MacroGenics, Inc. (MGNX) Stock Price

MGNXStock

$3.25+92.31%52W

Market Cap$207.03M

P/E—

PEG Ratio—

Div yield—

Beta1.26

MGNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-16.78%

Price vs S&P 500 (4W)-19.79%

VGM Score58.42

Book Value / Share (Quarterly)$0.67

P/TBV (Annual)3.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.53%

Cash Flow / Share (Quarterly)$-1.03

Price vs S&P 500 (YTD)89.94%

Gross Margin (TTM)74.45%

Net Profit Margin (TTM)-8.70%

EPS (TTM)$-0.23

10-Day Avg Trading Volume0.57M

EPS Excl Extra (TTM)$-0.23

Revenue Growth (5Y)7.34%

EPS (Annual)$-1.18

ROI (Annual)-59.42%

Gross Margin (Annual)75.91%

Net Profit Margin (5Y Avg)-89.99%

Cash / Share (Quarterly)$2.72

Revenue Growth QoQ (YoY)47.62%

ROA (Last FY)-29.05%

Revenue Growth TTM (YoY)1.32%

EBITD / Share (TTM)$-1.38

ROE (5Y Avg)-73.32%

Operating Margin (TTM)-55.77%

Cash Flow / Share (Annual)$-1.31

P/B Ratio4.83x

P/B Ratio (Quarterly)6.85x

Net Income / Employee (Annual)$-254,700

EV / Revenue (TTM)1.62x

Net Interest Coverage (TTM)-13.74x

ROA (TTM)-5.35%

EPS Growth QoQ (YoY)-70.10%

EV / EBITDA (TTM)4.92x

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)2.92x

3-Month Avg Trading Volume0.77M

52-Week Price Return92.31%

Revenue / Employee (TTM)$572,300

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)1.38x

Asset Turnover (Annual)0.58x

52-Week High$5.08

Operating Margin (5Y Avg)-93.94%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-20.19%

Tangible BV CAGR (5Y)-13.85%

26-Week Price Return-6.88%

Quick Ratio (Annual)4.71x

13-Week Price Return-27.62%

Total Debt / Equity (Annual)1.26x

Current Ratio (Quarterly)2.96x

Enterprise Value$271.27M

Revenue / Share Growth (5Y)3.41%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)-30.10%

Revenue / Employee (Annual)$510,200

Inventory Turnover (Annual)9.10x

Pretax Margin (Annual)-50.36%

Cash / Share (Annual)$3.00

3-Month Return Std Dev64.14%

Gross Margin (5Y Avg)89.11%

Net Income / Employee (TTM)$-49,800

ROE (Last FY)-134.23%

Net Interest Coverage (Annual)-5.19x

EPS Basic Excl Extra (Annual)$-1.18

P/FCF (TTM)4.84x

Receivables Turnover (TTM)9.03x

EV / Free Cash Flow (TTM)3.52x

Total Debt / Equity (Quarterly)4.16x

EPS Incl Extra (TTM)$-0.23

Receivables Turnover (Annual)16.91x

ROI (TTM)-10.17%

P/S Ratio (TTM)1.23x

Pretax Margin (5Y Avg)-89.96%

Revenue / Share (Annual)$2.37

Tangible BV / Share (Annual)$2.30

Price vs S&P 500 (52W)76.78%

Year-to-Date Return101.86%

5-Day Price Return-12.63%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-32.14%

Net Profit Margin (Annual)-49.91%

Month-to-Date Return-15.80%

Cash Flow / Share (TTM)$0.98

EBITD / Share (Annual)$-1.04

Operating Margin (Annual)-48.72%

LT Debt / Equity (Annual)1.26x

ROI (5Y Avg)-58.36%

LT Debt / Equity (Quarterly)3.81x

EPS Basic Excl Extra (TTM)$-0.23

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)1.83x

Inventory Turnover (TTM)4.24x

Pretax Margin (TTM)-62.34%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)-30.30%

Beta1.26x

P/FCF (Annual)33.07x

Revenue / Share (TTM)$2.64

ROE (TTM)-31.27%

52-Week Low$1.29

vGradeB

gGradeC

mGradeC

vgmGradeC

MGNX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	$0.26	$1.14	+341.36%(+$0.88)
Q1 2026	May 13, 2026	-$0.55	-$0.58	-5.94%(-$0.03)
Q4 2025	Mar 9, 2026	-$0.02	-$0.22	-1000.00%(-$0.20)
Q3 2025	Nov 12, 2025	-$0.51	$0.27	+153.47%(+$0.78)
Q2 2025	Aug 14, 2025	$0.38	-$0.57	-250.00%(-$0.95)

MGNX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.85

3.86

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
MGNXMacroGenics, Inc.	B	C	C	1.2x	1.3%	74.5%	—	$3.25
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About MacroGenics, Inc.

Macrogenics Inc. is a biotechnology company developing antibody-based therapeutics for cancer treatment. The company's marketed product, MARGENZA, is approved for metastatic HER2-positive breast cancer. Its pipeline includes three clinical-stage candidates: lorigerlimab, a bispecific DART targeting immune checkpoints PD-1 and CTLA-4; MGC026, targeting B7-H3; and MGC028, targeting ADAM9, each utilizing novel topoisomerase I inhibitor-based linker-payloads.

MGNX Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.13

Revenue estimate$39.18M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

MGNX Insider Transactions

SellAug 19, 2026
PETERS JEFFREY STUART
General Counsel
Shares: 31,105Value: $129,086

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

SABSSAB Biotherapeutics, Inc. Common StockBiological Products
LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$1.29

High$5.08